SBIR-STTR Award

Robotic scanner-analyzer for rapid, on-the-fly testing for tablet formulation and quality control in pharmaceutical manufacturing
Award last edited on: 11/8/2017

Sponsored Program
SBIR
Awarding Agency
NIH : NIMHD
Total Award Amount
$65,290
Award Phase
1
Solicitation Topic Code
FDA
Principal Investigator
Rudy Hofmeister

Company Information

H2OPTX INC (AKA: H2OPTX)

6830 Via Del Oro Suite 200
San Jose, CA 95119
   (760) 877-0010
   N/A
   www.h2optx.com
Location: Single
Congr. District: 19
County: Santa Clara

Phase I

Contract Number: 1R43FD006128-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2017
Phase I Amount
$65,290
Continuous manufacturing (CM) is attracting increasing attention within the pharmaceutical industry today because it could lead to significant decreases in production costs while improving product quality. The shift towards continuous manufacturing processes increases the number of required measurements. While batch processing utilizes a “hold and test” approach, continuous manufacturing requires consistent testing at many steps. This continuous testing approach requires complex machine interfaces to sample the product. In addition, the shift towards biologics based drug formulations has dramatically increased the complexity and frequency of measurements required during manufacturing. The complexity and risks associated with biologics increases the number of testing steps to ~250 as compared to ~50 steps for small molecules. As a result, new innovative instruments are needed to meet the demands of current pharmaceutical manufacturing, R&D and quality control. H2Optx Inc. proposes to develop a new automated multiplexed/hyperspectral imager-based scanner-analyzer that tie pharmaceutical manufacturing parameters to observed structures in powders and tablets. The contribution of the proposed research is expected to be that by developing the scanner-analyzer would significantly contribute to the current pharmaceutical manufacturing needs allowing to enhance process reliability and flexibility, drug quality monitoring and speeding up the drug R&D efforts.

Public Health Relevance Statement:
PROJECT NARRATIVE As a result of the shift towards continuous manufacturing processes and towards biologics based drug formulations, new innovative instruments are needed to meet the demands of current pharmaceutical manufacturing, R&D and quality control. The contribution of the proposed research is expected to be that by developing the scanner-analyzer would significantly contribute to the current pharmaceutical manufacturing needs allowing to enhance process reliability and flexibility, drug quality monitoring and speeding up the drug R&D efforts. The proposed scanner-analyzer would be a new automated multiplexed/hyperspectral imager- based system with unsurpassed sensitivity, speed and analysis capabilities.

Project Terms:
No Project Terms available.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----